Cluster Headache Market To Reach $1.45 Billion by 2035

Cluster headache market was valued at $0.78 billion in 2025 and is projected to reach $1.45 billion by 2035, expanding at a CAGR of 6.4% during the forecast period (2026–2035). The market growth is primarily driven by the increasing burden of neurological disorders and the rising demand for effective pain management therapies. According to the World Health Organization (WHO), neurological conditions account for nearly 6.3% of the global disease burden, highlighting the need for targeted treatment solutions such as cluster headache therapies.

Browse the full report description of “Cluster Headache Market Size, Share & Trends Analysis Report, By Treatment Type (Acute Treatment, Preventive Treatment, Transitional Treatments), By Disease Type (Episodic Cluster Headache, Chronic Cluster Headache), By Drug Type (Fast-Acting Drugs, Long-Term Drugs, Short-Term Drugs), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/cluster-headache-market

Increasing Investment and Innovations in Pharmaceuticals

A key macro driver supporting market expansion is the growing investment in pharmaceutical innovation. The European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that pharmaceutical R&D expenditure in Europe exceeded €52.4 billion, reflecting strong innovation pipelines, particularly in neurology. This surge in research funding is accelerating the development of advanced therapies such as CGRP inhibitors and fast-acting drugs for acute cluster headache treatment. Additionally, the U.S. Food and Drug Administration (FDA) continues to approve novel neurological drugs, supporting market accessibility and adoption.

Among the segments, the fast-acting drugs segment under drug type is expected to witness the fastest growth. These therapies are critical for immediate pain relief during acute cluster headache attacks, making them highly preferred in emergency and home care settings. Innovations in injectable and nasal delivery systems are improving drug efficacy and patient compliance, further driving segment growth.

Key Innovations by Market Players 

Market players are actively adopting strategic initiatives to strengthen their market presence. A few of the strategies are given below: -

• In June 2025, Eli Lilly and Company announced a definitive agreement to acquire Verve Therapeutics for approximately $1.0 billion (up to $1.3 billion including contingent payments). The acquisition aims to integrate Verve’s world-class gene-editing expertise with Lilly’s established cardiometabolic capabilities.
• In October 2023, Novartis AG leveraged its Sandoz spin-off to pivot toward high-value biologics, maintaining a strong R&D presence in neuro-inflammation and CGRP-pathway innovation.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o Treatment Type
  o Disease Type
  o Drug Type
  o Competitive Landscape – Eli Lilly and Company, GlaxoSmithKline (GSK), AbbVie (Allergan portfolio), Lundbeck, Novartis AG, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cluster Headache Market Report Segment

By Treatment Type

• Acute Treatment
• Preventive Treatment
• Transitional Treatments

By Disease Type

• Episodic Cluster Headache
• Chronic Cluster Headache

By Drug Type

• Fast-Acting Drugs
• Long-Term Drugs
• Short-Term Drugs

By End User

• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Cluster Headache Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cluster-headache-market